Ocera Therapeutics Company Profile (NASDAQ:OCRX)

About Ocera Therapeutics

Ocera Therapeutics logoOcera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger. It is conducting a randomized, placebo-controlled double blind Phase IIb clinical trial to evaluate the efficacy of intravenous administration of OCR-002 IV formulation in reducing the severity of HE symptoms among HE patients. The Company also conducted a Phase IIa investigator-sponsored trial of OCR-002 in Spain in patients with upper gastrointestinal bleeding associated with liver cirrhosis. It is developing an oral form of OCR-002 to provide continuity of care for HE patients, where the intravenous form is used for hospital-based acute care and the oral form for chronic maintenance care post discharge.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: OCRX
  • CUSIP:
Key Metrics:
  • Previous Close: $0.64
  • 50 Day Moving Average: $1.38
  • 200 Day Moving Average: $2.12
  • 52-Week Range: $0.52 - $3.90
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.56
  • P/E Growth: 0.00
  • Market Cap: $14.81M
  • Outstanding Shares: 23,143,000
  • Beta: 2.17
Profitability:
  • Net Margins: -23,816.53%
  • Return on Equity: -116.62%
  • Return on Assets: -73.71%
Debt:
  • Debt-to-Equity Ratio: 0.41%
  • Current Ratio: 4.57%
  • Quick Ratio: 4.57%
Additional Links:
Companies Related to Ocera Therapeutics:

Analyst Ratings

Consensus Ratings for Ocera Therapeutics (NASDAQ:OCRX) (?)
Ratings Breakdown: 2 Hold Ratings, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $5.80 (806.25% upside)

Analysts' Ratings History for Ocera Therapeutics (NASDAQ:OCRX)
Show:
DateFirmActionRatingPrice TargetDetails
1/31/2017HC WainwrightReiterated RatingBuy$10.00 -> $4.00View Rating Details
1/31/2017AegisReiterated RatingBuy$8.00 -> $3.00View Rating Details
1/31/2017JMP SecuritiesDowngradeOutperform -> Market PerformView Rating Details
1/30/2017Stifel NicolausDowngradeBuy -> Hold$1.00View Rating Details
10/24/2016Brean CapitalSet Price TargetBuy$10.00View Rating Details
3/6/2016Cowen and CompanyReiterated RatingBuy$11.00View Rating Details
(Data available from 2/23/2015 forward)

Earnings

Earnings History for Ocera Therapeutics (NASDAQ:OCRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/1/2017        
4/29/2016Q1($0.33)($0.36)ViewN/AView Earnings Details
3/3/2016Q415($0.33)($0.34)ViewN/AView Earnings Details
8/3/2015Q215($0.40)($0.46)ViewN/AView Earnings Details
4/30/2015Q115($0.29)($0.34)ViewN/AView Earnings Details
3/11/2015Q414($0.46)($0.28)ViewN/AView Earnings Details
11/13/2014Q314($0.50)($0.34)ViewN/AView Earnings Details
8/11/2014Q114($0.45)($0.46)ViewN/AView Earnings Details
5/8/2014($0.43)($0.27)ViewN/AView Earnings Details
3/13/2014Q413($0.21)($0.48)$2.93 million$52.00 millionViewN/AView Earnings Details
11/13/2013Q3 13($0.77)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ocera Therapeutics (NASDAQ:OCRX)
Current Year EPS Consensus Estimate: $-1.35 EPS
Next Year EPS Consensus Estimate: $-1.14 EPS

Dividends

Dividend History for Ocera Therapeutics (NASDAQ:OCRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Ocera Therapeutics (NASDAQ:OCRX)
Insider Ownership Percentage: 6.10%
Institutional Ownership Percentage: 35.00%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/7/2016Linda S GraisInsiderBuy7,000$2.14$14,980.00View SEC Filing  
10/13/2016Stan BukofzerInsiderBuy2,500$2.64$6,600.00View SEC Filing  
3/4/2016Linda S GraisCEOBuy3,000$3.19$9,570.00View SEC Filing  
1/22/2016Linda S GraisCEOBuy10,000$2.38$23,800.00View SEC Filing  
1/15/2016Gaurav AggarwalInsiderBuy10,000$2.15$21,500.00View SEC Filing  
1/15/2016Michael ByrnesCFOBuy3,500$2.07$7,245.00View SEC Filing  
6/23/2015Wendall WierengaDirectorBuy5,000$3.71$18,550.00View SEC Filing  
5/7/2015Rajiv PatniInsiderBuy5,050$3.97$20,048.50View SEC Filing  
5/6/2015Gaurav AggarwalInsiderBuy7,500$3.62$27,150.00View SEC Filing  
5/6/2015Linda S GraisCEOBuy30,000$3.73$111,900.00View SEC Filing  
5/6/2015Michael ByrnesCFOBuy2,500$3.61$9,025.00View SEC Filing  
10/1/2014Michael ByrnesVPBuy2,000$4.81$9,620.00View SEC Filing  
7/11/2014Linda S GraisCEOBuy10,000$5.93$59,300.00View SEC Filing  
7/11/2014Sharon TetlowCFOBuy3,000$5.83$17,490.00View SEC Filing  
7/15/2013Brian K HalakMajor ShareholderBuy995,618$6.03$6,003,576.54View SEC Filing  
7/15/2013Michael PowellDirectorBuy391,166$6.03$2,358,730.98View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Ocera Therapeutics (NASDAQ:OCRX)
DateHeadline
News IconSteering Attention Towards Earnings; Analysts Weigh in on Ocera Therapeutics, Inc. (NASDAQ:OCRX) Stock - Aiken Advocate (NASDAQ:OCRX)
aikenadvocate.com - February 21 at 5:53 PM
News IconAll You Need To Know About Ocera Therapeutics, Inc. (OCRX) Revealed Perfectly In The Charts - NY Stock News (NASDAQ:OCRX)
nystocknews.com - February 21 at 5:53 PM
News IconInvestor Investigation over possible Securities Laws Violations by Ocera Therapeutics Inc (NASDAQ:OCRX) (NASDAQ:OCRX)
www.groundreport.com - February 16 at 11:34 PM
News IconTrading Monitor: Watching Shares of Ocera Therapeutics Inc. (OCRX) - Baxter Review (NASDAQ:OCRX)
baxternewsreview.com - February 16 at 6:33 PM
News IconImpact of Brokerage Rating on Ocera Therapeutics, Inc.(OCRX) - Morning Outlook (NASDAQ:OCRX)
www.morningoutlook.com - February 15 at 3:28 AM
News IconSell-side is Weighing in on Ocera Therapeutics, Inc. (NASDAQ:OCRX) Earnings & Targets - Aiken Advocate (NASDAQ:OCRX)
aikenadvocate.com - February 14 at 10:20 PM
istreetwire.com logoStock's Trend Analysis Report: Zendesk, Inc. (ZEN), Ocera Therapeutics, Inc. (OCRX), The Gap, Inc. (GPS) - iStreetWire (NASDAQ:OCRX)
istreetwire.com - February 11 at 12:59 AM
News IconSteady Movements Ocera Therapeutics Inc (NASDAQ:OCRX ... - Financial Breaking News (NASDAQ:OCRX)
wsbreakingnews.com - February 11 at 12:59 AM
wallstrt24.com logoYesterday's Attention Gainers Ocera Therapeutics Inc (NASDAQ ... - Wall Street 24 (NASDAQ:OCRX)
wallstrt24.com - February 10 at 1:06 AM
sbwire.com logoNASDAQ:OCRX Shareholder Alert: Investigation over Possible Securities Laws Violations by Ocera Therapeutics Inc (NASDAQ:OCRX)
www.sbwire.com - February 9 at 8:05 PM
istreetwire.com logo3 Stocks in Focus: Sprouts Farmers Market, Inc. (SFM), Ocera Therapeutics, Inc. (OCRX), Finisar Corporation (FNSR) - iStreetWire (NASDAQ:OCRX)
istreetwire.com - February 8 at 7:56 PM
smarteranalyst.com logoWhat Sell-Side Analysts Think About Ocera Therapeutics Inc (OCRX) Following Recent Clinical Setback - Smarter Analyst (NASDAQ:OCRX)
www.smarteranalyst.com - February 8 at 7:56 PM
News IconEarnings Forecast Research on Ocera Therapeutics, Inc. (OCRX) - Morning Outlook (NASDAQ:OCRX)
www.morningoutlook.com - February 3 at 5:57 AM
businesswire.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Ocera ... (NASDAQ:OCRX)
www.businesswire.com - February 2 at 7:52 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Ocera Therapeutics, Inc. (NASDAQ:OCRX)
finance.yahoo.com - February 2 at 7:52 PM
News IconOcera Therapeutics, Inc. (OCRX) Broker Price Targets For The Coming Week (NASDAQ:OCRX)
mundoaguaysaneamiento.net - February 1 at 8:08 PM
News IconStock Running On Fumes, Touches a New Low: Ocera Therapeutics, Inc. (NASDAQ:OCRX) - Wall Street Beacon (NASDAQ:OCRX)
wsbeacon.com - February 1 at 6:14 AM
istreetwire.com logoStocks on the Move: Ocera Therapeutics, Inc. (OCRX), Exelixis, Inc. (EXEL), Dynegy Inc. (DYN) - iStreetWire (NASDAQ:OCRX)
istreetwire.com - February 1 at 6:14 AM
finance.yahoo.com logoOcera Therapeutics downgraded by JMP Securities (NASDAQ:OCRX)
finance.yahoo.com - January 31 at 7:58 PM
streetinsider.com logoForm 8-K Ocera Therapeutics, Inc. For: Jan 30 - StreetInsider.com (NASDAQ:OCRX)
www.streetinsider.com - January 31 at 8:01 AM
streetinsider.com logoJMP Securities Downgrades Ocera Therapeutics (OCRX) to Market Perform - StreetInsider.com (NASDAQ:OCRX)
www.streetinsider.com - January 31 at 8:01 AM
rttnews.com logoOcera Therapeutics Inc. (OCRX) Sank To A New Low On Phase 2 Study Results - RTT News (NASDAQ:OCRX)
www.rttnews.com - January 31 at 8:01 AM
streetinsider.com logoPre-Open Movers 01/30: (CALA) (DHT) (XXIA) Higher; (OCRX) (RGLS) (TPX) Lower (more...) (NASDAQ:OCRX)
www.streetinsider.com - January 31 at 12:43 AM
nasdaq.com logoBUZZ-U.S. STOCKS ON THE MOVE-Rite Aid, Calithera, Ocera, Ixia - Nasdaq (NASDAQ:OCRX)
www.nasdaq.com - January 30 at 7:40 PM
seekingalpha.com logoOcera's lead product candidate flunks mid-stage HE study; shares plummet 59% premarket - Seeking Alpha (NASDAQ:OCRX)
seekingalpha.com - January 30 at 7:40 PM
News IconCalibrating the Trade: Watching Technicals on Shares of Ocera Therapeutics Inc. (OCRX) - Sherwood Daily (NASDAQ:OCRX)
sherwooddaily.com - January 30 at 7:40 PM
smarteranalyst.com logoMonday's Biotech Insights: Pulmatrix Inc (PULM), Regulus (RGLS), Ocera Therapeutics (OCRX) - Smarter Analyst (NASDAQ:OCRX)
www.smarteranalyst.com - January 30 at 7:40 PM
streetinsider.com logoOcera's (OCRX) Phase 2b Study of OCR-002 in Hepatic Encephalopathy Wasn't Statistically Significant in Primary and Secondary Endpoints (NASDAQ:OCRX)
www.streetinsider.com - January 30 at 8:48 AM
us.rd.yahoo.com logo7:00 am Ocera Therapeutics announces top-line results for Phase 2b study in Hepatic Encephalopathy; primary and secondary endpoints showed trend and dose-related clinical benefit although not statistically significant (shares halted) (NASDAQ:OCRX)
us.rd.yahoo.com - January 30 at 8:48 AM
News IconStock Momentum in Focus on Shares of Ocera Therapeutics Inc. (OCRX) - Sherwood Daily (NASDAQ:OCRX)
sherwooddaily.com - January 28 at 5:25 AM
News IconInvestor Corner: Checking in on Shares of Ocera Therapeutics Inc. (OCRX) - Sherwood Daily (NASDAQ:OCRX)
sherwooddaily.com - January 27 at 5:03 AM
News IconInvestor Notebook: Focusing in on Shares of Ocera Therapeutics Inc. (OCRX) - Sherwood Daily (NASDAQ:OCRX)
sherwooddaily.com - January 25 at 12:46 AM
News IconLooking at Moving Averages for Ocera Therapeutics Inc. (OCRX) - Sherwood Daily (NASDAQ:OCRX)
sherwooddaily.com - January 24 at 12:21 AM
News IconWall Street Holds Inauguration Gains, How Did This Stock Fare: Ocera Therapeutics, Inc. (NASDAQ:OCRX) - Wall Street Beacon (NASDAQ:OCRX)
wsbeacon.com - January 22 at 1:28 AM
News IconTrading Views: Checking the Numbers for Ocera Therapeutics Inc. (OCRX) - Sherwood Daily (NASDAQ:OCRX)
sherwooddaily.com - January 21 at 7:18 AM
capitalcube.com logoETFs with exposure to Ocera Therapeutics, Inc. : January 19, 2017 (NASDAQ:OCRX)
www.capitalcube.com - January 19 at 11:36 PM
News IconFollowing the Charts on Shares of Ocera Therapeutics Inc. (OCRX) - Sherwood Daily (NASDAQ:OCRX)
sherwooddaily.com - January 19 at 12:37 AM
News IconTop Rated Stock With Earnings Growth & Implied Upside: Ocera Therapeutics, Inc. (NASDAQ:OCRX) - Prospect Journal (NASDAQ:OCRX)
prospectjournal.com - January 17 at 11:22 AM
News IconSell-side Consensus Sees Ocera Therapeutics, Inc. (NASDAQ:OCRX) Going Where Near-Term? - Aiken Advocate (NASDAQ:OCRX)
aikenadvocate.com - January 17 at 11:22 AM
News IconCan This Stock Price Climb The Ladder: Ocera Therapeutics, Inc. (NASDAQ:OCRX) - Prospect Journal (NASDAQ:OCRX)
prospectjournal.com - January 12 at 7:38 PM
News IconCan This Stock Gain Any Traction: Ocera Therapeutics, Inc ... - Prospect Journal (NASDAQ:OCRX)
prospectjournal.com - January 12 at 12:39 AM
News IconNotable Stock For Under $5: Ocera Therapeutics, Inc. (NASDAQ:OCRX) - Prospect Journal (NASDAQ:OCRX)
prospectjournal.com - January 10 at 8:46 AM
marketexclusive.com logoOCERA THERAPEUTICS, INC. (NASDAQ:OCRX) Files An 8-K ... - Market Exclusive (NASDAQ:OCRX)
marketexclusive.com - January 10 at 8:46 AM
biz.yahoo.com logoOCERA THERAPEUTICS, INC. Files SEC form 8-K, Other Events (NASDAQ:OCRX)
biz.yahoo.com - January 9 at 7:41 PM
streetinsider.com logoOcera Therapeutics (OCRX) Announces Positive Phase 1 Clinical Study of Orally-Administered OCR-002 (NASDAQ:OCRX)
www.streetinsider.com - January 6 at 7:42 PM
streetinsider.com logoOcera Therapeutics (OCRX) Announces Positive Phase 1 Clinical Study of Orally-Administered OCR-002 - StreetInsider.com (NASDAQ:OCRX)
www.streetinsider.com - January 5 at 11:07 PM
finance.yahoo.com logo9:06 am Ocera Therapeutics announces 'successful' Phase 1 Clinical Study of Orally-Administered OCR-002 in Patients with Cirrhosis -- Data Support Feasibility of Oral OCR-002 as maintenance therapy for patients with hepatic encephalopathy; (NASDAQ:OCRX)
finance.yahoo.com - January 5 at 11:07 PM
publicnow.com logoOcera Announces Successful Phase 1 Clinical Study of Orally-Administered OCR-002 in Patients with Cirrhosis (NASDAQ:OCRX)
www.publicnow.com - January 5 at 11:07 PM
News IconOcera Therapeutics Inc. (OCRX) Stock Moves Down and Here's Why - BNB Daily (blog) (NASDAQ:OCRX)
www.baseball-news-blog.com - January 1 at 7:14 PM
capitalcube.com logoETFs with exposure to Ocera Therapeutics, Inc. : December 29, 2016 (NASDAQ:OCRX)
www.capitalcube.com - December 29 at 6:56 PM

Social

What is Ocera Therapeutics' stock symbol?

Ocera Therapeutics trades on the NASDAQ under the ticker symbol "OCRX."

Where is Ocera Therapeutics' stock going? Where will Ocera Therapeutics' stock price be in 2017?

6 brokers have issued 12 month target prices for Ocera Therapeutics' shares. Their forecasts range from $1.00 to $11.00. On average, they expect Ocera Therapeutics' stock price to reach $5.80 in the next twelve months.

When will Ocera Therapeutics announce their earnings?

Ocera Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March, 1st 2017.

Who owns Ocera Therapeutics stock?

Ocera Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Interwest Venture Management Co. (5.39%), Deerfield Management Co. (2.48%), Renaissance Technologies LLC (0.95%) and Vivo Capital LLC (0.66%). Company insiders that own Ocera Therapeutics stock include Gaurav Aggarwal, Linda S Grais, Michael Byrnes, Rajiv Patni, Stan Bukofzer and Wendall Wierenga.

Who bought Ocera Therapeutics stock? Who is buying Ocera Therapeutics stock?

Ocera Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Interwest Venture Management Co. and Renaissance Technologies LLC. Company insiders that have bought Ocera Therapeutics stock in the last two years include Gaurav Aggarwal, Linda S Grais, Michael Byrnes, Rajiv Patni, Stan Bukofzer and Wendall Wierenga.

How do I buy Ocera Therapeutics stock?

Shares of Ocera Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Ocera Therapeutics stock cost?

One share of Ocera Therapeutics stock can currently be purchased for approximately $0.64.

Ocera Therapeutics (NASDAQ:OCRX) Chart for Thursday, February, 23, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Ocera Therapeutics (NASDAQ:OCRX)

Earnings History Chart

Earnings by Quarter for Ocera Therapeutics (NASDAQ:OCRX)

Dividend History Chart

Dividend Payments by Quarter for Ocera Therapeutics (NASDAQ:OCRX)

Last Updated on 2/23/2017 by MarketBeat.com Staff